Don't Just Read the News, Understand It.
Published loading...Updated

The King of Ozempic Is Scared as Hell

Summary by Wired
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

4 Articles

All
Left
2
Center
Right
Lean Left

Novo Nordisk, Europe's largest capitalisation company, has achieved worse results than expected in its new slimming drug: Cagrisema

·Spain
Read Full Article

"Ozempic's unexpected increase in demand has presented a challenge in the availability of treatment for people with diabetes, who depend on this medication to control their disease." This was assured by Francisco Pajuelo, medical director of Novo Nordisk Spain, who has pointed out to Medical Writing the measures they have taken from the company to ensure that both people with type 2 diabetes and those with obesity or overweight have adequate the…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Wired broke the news in United States on Monday, January 13, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.